P

Usamos cookies essenciais, analíticas e publicidade para melhorar a experiência, medir a utilização e otimizar campanhas.

Saiba mais em Política de Privacidade · Termos de Serviço · Política de Cookies

Guardar

Pending

HORIZON-MISS-2027-02-CANCER-03International

Pending

Biomarker-guided clinical trials for rare and very rare cancers

Horizon Europe

Description

Europe

Health & Life Sciences•100% • 24M€

Pending

Dates & Deadlines

Publication Date

October 5, 2026

Opening Date

February 10, 2027

Application Phases

Fase única

September 16, 2027 at 05:00 PM

Financial Details

Non-Refundable

Maximum Funding Rate

100%

Budget

24M€

Eligible Project Value

7M€ - 9M€

Criteria & Documents

Eligible Expenses

●Personnel Costs
●Travel costs
●Equipment costs
●Other goods, works and services costs
●Subcontracting
●Indirect Costs
●Preclinical research
●Clinical trial costs
●Networking and meetings
●Stakeholder engagement
●Data management
●Regulatory consultation costs
●Open data infrastructure
●Patient and caregiver involvement activities

Access Conditions

●Legal entities from EU Member States and Associated Countries
●Consortium must include partners from at least three different EU Member States or Associated Countries
●Compliance with general and specific admissibility and eligibility criteria

Selection Criteria

●Excellence (scientific and technical merit)
●Impact (contribution to policy and partnership KPIs)
●Quality and efficiency of implementation

Mandatory Information

●Application form (Part A and Part B)
●Budget

Bonuses & Majorations

●Participation in EU Cancer Mission 'Diagnosis and treatment' cluster
●Collaboration with Knowledge Centre on Cancer resources

Result Indicators

●Improved access for rare cancer patients to innovative treatments
●Number of validated clinical trial protocols conducted
●Data contributions to European Health Data Space
●Integration into UNCAN.eu platform
●Stakeholder participation and engagement metrics

EU Programme Details

Call ID: HORIZON-MISS-2027-02-CANCER-03
Cluster: Mission
Destination: Cancer
Submission Mode: Single-stage
EU Contribution: Around €7,000,000.00 to €9,000,000.00 per project
Expected Projects: 3 projects
Funding Rate Rule: Up to 100% of eligible costs for Research and Innovation Actions (RIA)

Guardar

Pending

HORIZON-MISS-2027-02-CANCER-03International

Pending

Biomarker-guided clinical trials for rare and very rare cancers

Horizon Europe

Description

Europe

Health & Life Sciences•100% • 24M€

Pending

Dates & Deadlines

Publication Date

October 5, 2026

Opening Date

February 10, 2027

Application Phases

Fase única

September 16, 2027 at 05:00 PM

Financial Details

Non-Refundable

Maximum Funding Rate

100%

Budget

24M€

Eligible Project Value

7M€ - 9M€

Criteria & Documents

Eligible Expenses

●Personnel Costs
●Travel costs
●Equipment costs
●Other goods, works and services costs
●Subcontracting
●Indirect Costs
●Preclinical research
●Clinical trial costs
●Networking and meetings
●Stakeholder engagement
●Data management
●Regulatory consultation costs
●Open data infrastructure
●Patient and caregiver involvement activities

Access Conditions

●Legal entities from EU Member States and Associated Countries
●Consortium must include partners from at least three different EU Member States or Associated Countries
●Compliance with general and specific admissibility and eligibility criteria

Selection Criteria

●Excellence (scientific and technical merit)
●Impact (contribution to policy and partnership KPIs)
●Quality and efficiency of implementation

Mandatory Information

●Application form (Part A and Part B)
●Budget

Bonuses & Majorations

●Participation in EU Cancer Mission 'Diagnosis and treatment' cluster
●Collaboration with Knowledge Centre on Cancer resources

Result Indicators

●Improved access for rare cancer patients to innovative treatments
●Number of validated clinical trial protocols conducted
●Data contributions to European Health Data Space
●Integration into UNCAN.eu platform
●Stakeholder participation and engagement metrics

EU Programme Details

Call ID: HORIZON-MISS-2027-02-CANCER-03
Cluster: Mission
Destination: Cancer
Submission Mode: Single-stage
EU Contribution: Around €7,000,000.00 to €9,000,000.00 per project
Expected Projects: 3 projects
Funding Rate Rule: Up to 100% of eligible costs for Research and Innovation Actions (RIA)